MIKA Pharma GmbH - Product Pipeline Review - 2012

Global Markets Direct, June 2012, Pages: 29

MIKA Pharma GmbH – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “MIKA Pharma GmbH - Product Pipeline Review - 2012” provides data on the MIKA Pharma GmbH’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MIKA Pharma GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from MIKA Pharma GmbH and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- MIKA Pharma GmbH - Brief MIKA Pharma GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MIKA Pharma GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MIKA Pharma GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MIKA Pharma GmbH’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MIKA Pharma GmbH’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MIKA Pharma GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MIKA Pharma GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MIKA Pharma GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MIKA Pharma GmbH and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of MIKA Pharma GmbH; MIKA Pharma GmbH - Key Therapeutics; MIKA Pharma GmbH - Pipeline Overview and Promising Molecules; MIKA Pharma GmbH - News; MIKA Pharma GmbH - Latest Updates; MIKA Pharma GmbH - Pipeline; MIKA Pharma GmbH - Discontinued/Dormant Projects

List of Tables
List of Figures
MIKA Pharma GmbH Snapshot
MIKA Pharma GmbH Overview
Key Information
Key Facts
MIKA Pharma GmbH – Research and Development Overview
Key Therapeutic Areas
MIKA Pharma GmbH – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
MIKA Pharma GmbH – Pipeline Products Glance
MIKA Pharma GmbH – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
MIKA Pharma GmbH Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
MIKA Pharma GmbH – Drug Profiles
MK03
Product Description
Mechanism of Action
R&D Progress
MK22
Product Description
Mechanism of Action
R&D Progress
MK49
Product Description
Mechanism of Action
R&D Progress
MK50
Product Description
Mechanism of Action
R&D Progress
MK51
Product Description
Mechanism of Action
R&D Progress
MK52
Product Description
Mechanism of Action
R&D Progress
MIKA Pharma GmbH – Pipeline Analysis
MIKA Pharma GmbH – Pipeline Products by Therapeutic Class
MIKA Pharma GmbH – Pipeline Products By Target
MIKA Pharma GmbH – Pipeline Products by Route of Administration
MIKA Pharma GmbH – Pipeline Products By Mechanism of Action
MIKA Pharma GmbH – Locations And Subsidiaries
Head Office
Financial Deals Landscape
MIKA Pharma GmbH, Deals Summary
MIKA Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details
Partnerships
MIKA Pharma Enters Into Co-Development Agreement With GALENpharma
Acquisition
High Tech Beteiligungen Sells Mika Pharma To Giuliani
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
MIKA Pharma GmbH, Key Information
MIKA Pharma GmbH, Key Facts
MIKA Pharma GmbH – Pipeline by Indication, 2012
MIKA Pharma GmbH – Pipeline by Stage of Development, 2012
MIKA Pharma GmbH – Monotherapy Products in Pipeline, 2012
MIKA Pharma GmbH – Phase III, 2012
MIKA Pharma GmbH – Phase II, 2012
MIKA Pharma GmbH – Phase I, 2012
MIKA Pharma GmbH – Pipeline By Therapeutic Class, 2012
MIKA Pharma GmbH - Pipeline By Target, 2012
MIKA Pharma GmbH – Pipeline By Route of Administration, 2012
MIKA Pharma GmbH – Pipeline Products By Mechanism of Action, 2012
MIKA Pharma GmbH, Deals Summary
MIKA Pharma Enters Into Co-Development Agreement With GALENpharma
High Tech Beteiligungen Sells Mika Pharma To Giuliani

List of Figures
MIKA Pharma GmbH – Pipeline by Indication, 2012
MIKA Pharma GmbH – Pipeline by Stage of Development, 2012
MIKA Pharma GmbH – Monotherapy Products in Pipeline, 2012
MIKA Pharma GmbH – Pipeline By Therapeutic Class, 2012
MIKA Pharma GmbH - Pipeline By Target, 2012
MIKA Pharma GmbH – Pipeline By Route of Administration, 2012
MIKA Pharma GmbH - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Analysis of Google Inc
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model